Gene: ASB9

140462
-
ankyrin repeat and SOCS box containing 9
protein-coding
Xp22.2
Ensembl:ENSG00000102048 MIM:300890 Vega:OTTHUMG00000021172 UniprotKB:Q96DX5
NG_016218.1
PubMed
0   ANCO-SNPs
AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GADL10.822
SIX10.82
TNFAIP80.805
PZP0.804
PDE5A0.798
PARP150.794
LY750.788
GZMA0.785
PABPC4L0.784
BMP50.783

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASPDH-0.493
HHATL-0.456
FAM43B-0.452
FEZF2-0.444
GREB1-0.436
BDH1-0.436
DBP-0.435
OGDHL-0.424
CHRNA4-0.423
KLHL26-0.422

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C0326424-aminophenylarsenoxide4-aminophenylarsenoxide binds to ASB9 protein26598702
C0326424-aminophenylarsenoxidearsenic trioxide inhibits the reaction [4-aminophenylarsenoxide binds to ASB9 protein]26598702
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 affects the expression of ASB9 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of ASB9 mRNA21632981|2210060
C004984apocarotenalapocarotenal results in increased expression of ASB9 mRNA17034753
C006632arsenic trioxidearsenic trioxide inhibits the reaction [4-aminophenylarsenoxide binds to ASB9 protein]26598702
D001194AsbestosAsbestos affects the expression of ASB9 mRNA17297452
D001379AzathioprineAzathioprine results in decreased expression of ASB9 mRNA22623647
C547126AZM551248AZM551248 results in increased expression of ASB9 mRNA22323515
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ASB9 mRNA20106945|2163298
D019207beta Carotenebeta Carotene results in increased expression of ASB9 mRNA17034753
C006780bisphenol Abisphenol A results in decreased expression of ASB9 mRNA25181051
D003300Copper[NSC 689534 binds to Copper] which results in decreased expression of ASB9 mRNA20971185
D019327Copper SulfateCopper Sulfate results in decreased expression of ASB9 mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of ASB9 mRNA20106945|2163298
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of ASB9 mRNA27392435
D002945CisplatinCisplatin results in increased expression of ASB9 mRNA27392435
C000944dicrotophosdicrotophos results in decreased expression of ASB9 mRNA28302478
D005557FormaldehydeFormaldehyde results in increased expression of ASB9 mRNA23649840
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of ASB9 mRNA20044591
C492448ICG 001ICG 001 results in decreased expression of ASB9 mRNA26191083
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of ASB9 mRNA25613284
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of ASB9 mRNA27392435
C544151jinfukangjinfukang results in increased expression of ASB9 mRNA27392435
C008261lead acetatelead acetate results in increased expression of ASB9 mRNA22609695
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of ASB9 mRNA23649840
C523799MRK 003MRK 003 results in decreased expression of ASB9 mRNA21169257
D009532NickelNickel results in decreased expression of ASB9 mRNA24768652|2558310
C025256nonylphenolnonylphenol results in increased expression of ASB9 mRNA22982499
C558013NSC 689534[NSC 689534 binds to Copper] which results in decreased expression of ASB9 mRNA20971185
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C471071perfluorohexanesulfonic acidperfluorohexanesulfonic acid results in decreased expression of ASB9 mRNA22790973
C101814perfluoro-n-undecanoic acidperfluoro-n-undecanoic acid results in increased expression of ASB9 mRNA23602845
D010634PhenobarbitalNR1I3 protein affects the reaction [Phenobarbital results in decreased expression of ASB9 mRNA]19482888
D010634PhenobarbitalPhenobarbital results in decreased expression of ASB9 mRNA19482888
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of ASB9 mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ASB9 mRNA19710929
D011794QuercetinQuercetin results in decreased expression of ASB9 mRNA21632981
C016104sodium bichromatesodium bichromate results in increased expression of ASB9 mRNA22155349
D053260SootSoot results in increased expression of ASB9 mRNA26551751
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ASB9 mRNA20106945|2163298
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ASB9 mRNA16962184
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of ASB9 mRNA25613284
D014212TretinoinTretinoin results in decreased expression of ASB9 mRNA23724009
C012589trichostatin Atrichostatin A results in increased expression of ASB9 mRNA24935251
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of ASB9 mRNA"26179874
D014520UrethaneUrethane results in decreased expression of ASB9 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ASB9 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of ASB9 mRNA23179753|2438349
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of ASB9 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI16189514  19060904  21516116  25416956  25814554  
GO ID GO Term Qualifier Evidence PubMed
GO:0016567protein ubiquitination-IBA21873635  
GO:0016567protein ubiquitination-IDA17148442  
GO:0016567protein ubiquitination-IEA-  
GO:0035556intracellular signal transduction-IEA-  
GO:0043687post-translational protein modification-TAS-  
GO:0045732positive regulation of protein catabolic process-IBA21873635  
GO:0045732positive regulation of protein catabolic process-IDA17148442  
GO ID GO Term Qualifier Evidence PubMed
GO:0005739mitochondrion-IEA-  
GO:0005829cytosol-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-8951664NeddylationTAS
R-HSA-983168Antigen processing: Ubiquitination & Proteasome degradationTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29132311Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI. (2017 Nov 13)Wang WBMC Genomics